Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...